Hepatic & Renal Function (Cystatin C, eGFR)

Navigation & Literature

• Parent Silo: 03 - Diagnostics & Quantified Self MOC
• Literature Dossier: Hepatic & Renal Function (Cystatin C, eGFR) - References

---

1. Reference Range Comparison (Standard vs. Longevity Optimal)

Sub-Marker	Standard Clinical Range	Longevity / Functional Optimal	Primary Unit	Physiological Meaning
Cystatin C	$0.53–1.02\text{ mg/L}$	$0.60–0.85\text{ mg/L}$	$\text{mg/L}$	Ubiquitous nucleated-cell protease inhibitor freely filtered by glomeruli (muscle-independent)
${\text{eGFR}}_{\text{cys}}$ / ${\text{eGFR}}_{\text{cr-cys}}$	$>60{\text{ mL/min/1.73m}}^2$	$>100{\text{ mL/min/1.73m}}^2$ ($>90$ over age 50)	${\text{mL/min/1.73m}}^2$	True glomerular filtration rate using CKD-EPI 2021 Cystatin C equation
Serum Creatinine	$0.70–1.30\text{ mg/dL}$ (M) / $0.55–1.10\text{ mg/dL}$ (F)	Contextualized by lean mass & creatine intake	$\text{mg/dL}$	Non-enzymatic breakdown product of skeletal muscle phosphocreatine
ALT (Alanine Aminotransferase)	$7–45\text{ U/L}$	$12–22\text{ U/L}$ (M) / $10–18\text{ U/L}$ (F)	$\text{U/L}$	Hepatocyte-specific cytosolic transaminase; primary marker of MASLD / liver fat
AST (Aspartate Aminotransferase)	$8–40\text{ U/L}$	$12–22\text{ U/L}$ ($\text{AST:ALT ratio}\approx 0.8–1.1$)	$\text{U/L}$	Cytosolic & mitochondrial transaminase in liver, skeletal muscle, and myocardium
Total Bilirubin	$0.2–1.2\text{ mg/dL}$	$0.5–1.2\text{ mg/dL}$ (Gilbert’s $1.2–2.2$ protective)	$\text{mg/dL}$	Heme breakdown byproduct; potent endogenous lipid-soluble antioxidant
Serum Albumin	$3.5–5.5\text{ g/dL}$	$4.5–5.2\text{ g/dL}$	$\text{g/dL}$	Hepatic synthetic reserve, oncotic pressure, and primary extracellular thiol antioxidant
UACR (Urine Albumin-to-Creatinine)	$<30\text{ mg/g}$	$<5.0\text{ mg/g}$	$\text{mg/g}$	Glomerular endothelial glycocalyx integrity and microvascular permeability

---

2. Physiological Significance & Hazard Curves

Why Cystatin C Supersedes Creatinine in Biohackers & Athletes

Standard clinical renal panels estimate GFR solely from serum creatinine (${\text{eGFR}}_{\text{cr}}$). However, creatinine is confounded in two directions crucial for longevity practitioners:

1. False Positive CKD in Athletes: Individuals with high appendicular skeletal muscle mass (see Body Composition (DEXA, Visceral Fat)), high dietary meat intake, or exogenous creatine supplementation ($5\text{ g/day}$ via Creatine & Phosphocreatine System) frequently exhibit serum creatinine of $1.15–1.35\text{ mg/dL}$ and a falsely depressed ${\text{eGFR}}_{\text{cr}}$ of $62–75{\text{ mL/min/1.73m}}^2$, despite pristine kidney function ($\text{Cystatin C }0.72\text{ mg/L}$, ${\text{eGFR}}_{\text{cys}}=115{\text{ mL/min/1.73m}}^2$).
2. Masked Renal Decline in Sarcopenia ($\Delta \text{eGFR}={\text{eGFR}}_{\text{cys}}-{\text{eGFR}}_{\text{cr}}$): Conversely, frail or sarcopenic individuals have low muscle mass and low creatinine, masking glomerular decline. When ${\text{eGFR}}_{\text{cys}}$ is $>15{\text{ mL/min/1.73m}}^2$ lower than ${\text{eGFR}}_{\text{cr}}$, all-cause mortality, heart failure hospitalization, and end-stage kidney disease hazard ratios surge by $1.6\times \text{ to }2.5\times$. Cystatin C is produced at a constant rate by all nucleated cells, making it the gold-standard endogenous filtration and cardiorenal aging marker.

Transaminases (ALT/AST) & Exercise vs. Hepatocyte Injury

Standard lab reference ranges for ALT ($<45\text{ U/L}$) were derived from populations with a 30% prevalence of subclinical fatty liver. True hepatocyte-healthy upper limits of normal (Prati criteria) are $<30\text{ U/L}$ in men and $<19\text{ U/L}$ in women, with longevity-optimal targets of $12–22\text{ U/L}$.

• Exercise Confounding: Heavy eccentric resistance training or marathon running releases AST and ALT from skeletal muscle alongside Creatine Kinase (CK) for up to 5–7 days post-workout (with AST typically rising more than ALT, whereas GGT remains completely normal).
• Sarcopenia Trap: Extremely low ALT ($<8–10\text{ U/L}$) in older adults is associated with higher frailty and mortality due to Pyridoxal-5’-Phosphate (Vitamin B6) deficiency and loss of metabolically active lean mass.

Serum Albumin & Mild Unconjugated Bilirubin (Gilbert’s Longevity Effect)

Serum albumin is a core input to the Levine PhenoAge biological clock: every $0.2\text{ g/dL}$ drop below $4.5\text{ g/dL}$ tracks with systemic inflammation (IL-6 suppresses hepatic albumin transcription) and higher mortality. Meanwhile, mild unconjugated hyperbilirubinemia ($1.2–2.2\text{ mg/dL}$ with normal AST/ALT/GGT, characteristic of benign UGT1A1 Gilbert’s syndrome) is associated with a 30–50% reduction in cardiovascular and all-cause mortality, as bilirubin scavenges peroxyl radicals and inhibits NADPH oxidase and LDL oxidation.

---

3. Root Causes of Dysregulation

• Elevated Cystatin C / Declining ${\text{eGFR}}_{\text{cys}}$ ($<90\text{ mL/min}$): Subclinical nocturnal hypertension or elevated arterial stiffness (Blood Pressure & Pulse Wave Velocity), hyperuricemia ($>5.5\text{ mg/dL}$ causing afferent arteriolar vasoconstriction), chronic NSAID or PPI exposure, and glycemic variability / AGEs damaging glomerular podocytes.
• Elevated ALT ($>25\text{ U/L}$) with Normal CK: Visceral adiposity and hepatic de novo lipogenesis (MASLD), excess fructose/alcohol, hepatotoxic xenobiotics/supplements, or choline/betaine deficiency impairing hepatic VLDL export (PEMT pathway).

---

4. Actionable Interventions

Foundational Protocols (01 - Foundations)

• Glomerular Hemodynamic Protection: Maintain optimal 24h blood pressure ($<115/75\text{ mmHg}$) and vascular elasticity via Zone 2 & VO2 Max, Hydration & Electrolytes, and Blood Pressure & Pulse Wave Velocity.
• Hepatic Lipid Clearance: Deplete intrahepatic triglycerides via Time-Restricted Feeding & Fasting and Metabolic Flexibility & Insulin Sensitivity (a 5–7% reduction in body weight reduces liver fat by 30–40% and normalizes ALT).
• Pre-Test Abstinence from Eccentric Lifting: Abstain from high-volume resistance training for 48–72 hours before hepatic panels to avoid skeletal-muscle AST/ALT elevation.

Molecular & Pharmacological Interventions (02 - Compounds & Molecules)

• Hepatocyte Membrane & Choline Support: Phosphatidylcholine / Citicoline or Alpha-GPC via Cholinergics (Alpha-GPC, Citicoline) plus TMG (Betaine) via Methylation & B-Complex to drive PEMT-mediated VLDL export out of the liver; TUDCA ($250–500\text{ mg}$), Silymarin (milk thistle), and NAC via Amino Acids & Precursors.
• Renal Microvascular & Endothelial Support: Low-dose Tadalafil ($2.5–5\text{ mg}$) or L-Citrulline ($3–6\text{ g/day}$) via PDE5 Inhibitors & Endothelial Function to enhance renal nitric oxide and lower UACR; SGLT2 inhibitors via AMPK & Glycemic Agents (Metformin, Berberine, Acarbose) reduce intraglomerular hyperfiltration pressure via tubuloglomerular feedback.

---

5. Key Scientific Evidence Summary

• Shlipak et al. (2013, NEJM): CKD Prognosis Consortium meta-analysis ($n=90,750$) proving Cystatin C reclassifies GFR and predicts all-cause and cardiovascular mortality far more accurately than creatinine across all GFR strata.
• Inker et al. (2021, NEJM): Established the race-free 2021 CKD-EPI combined creatinine–cystatin C equation as the most accurate estimator of measured GFR.
• Horsfall et al. (2013, JAMA): UK primary care cohort ($n=15,138$) demonstrating that Gilbert’s syndrome unconjugated bilirubin levels ($1.2–2.5\text{ mg/dL}$) confer a 36–50% reduction in all-cause mortality.

See full bibliographic details and quantitative effect sizes in Hepatic & Renal Function (Cystatin C, eGFR) - References.